BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML.
about
BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib.Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimizatiDasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response.Molecular measurement of BCR-ABL transcript variations in chronic myeloid leukemia patients in cytogenetic remission.Major molecular response in CML patients treated with tyrosine kinase inhibitors: the paradigm for monitoring targeted cancer therapyFlow Cytometric Immunobead Assay for Detection of BCR-ABL1 Fusion Proteins in Chronic Myleoid Leukemia: Comparison with FISH and PCR TechniquesLong-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)Monitoring of BCR-ABL levels in chronic myeloid leukemia patients treated with imatinib in the chronic phase - the importance of a major molecular responsePlanned pregnancy in a chronic myeloid leukemia patient in molecular remission.Exploratory study on the impact of switching to nilotinib in 18 patients with chronic myeloid leukemia in chronic phase with suboptimal response to imatinib.An intron-derived insertion/truncation mutation in the BCR-ABL kinase domain in chronic myeloid leukemia patients undergoing kinase inhibitor therapyKinetics of BCR-ABL Transcripts in Imatinib Mesylate treated Chronic Phase CML (CPCML), A Predictor of Response and Progression Free Survival.Predictive Value of Pretreatment BCR-ABL(IS) Transcript level on Response to Imatinib Therapy in Egyptian Patients with Chronic Phase Chronic Myeloid Leukemia (CPCML).Current practices in the management of chronic myeloid leukemia.How I monitor residual disease in chronic myeloid leukemia.Molecular monitoring in chronic myeloid leukemia: response to tyrosine kinase inhibitors and prognostic implications.Monitoring molecular response in chronic myeloid leukemiaSuboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy?Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.Genomic and proteomic biomarkers for cancer: a multitude of opportunities.Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinibAchieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib front-line therapySuboptimal responses in chronic myeloid leukemia: milestones and mechanisms.Evolution of definitions of response, progression-free survival and event-free survival in front-line studies of chronic myeloid leukemia.Molecular resistance: an early indicator for treatment change?BCR-ABL PCR testing in chronic myelogenous leukemia: molecular diagnosis for targeted cancer therapy and monitoring.Magnetic Nanoparticles PCR Enzyme-Linked Gene Assay for Quantitative Detection of BCR/ABL Fusion Gene in Chronic Myelogenous Leukemia.Incidence and clinical importance of BCR-ABL1 mutations in Iranian patients with chronic myeloid leukemia on imatinib.Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia.Chronic myeloid leukemia 2011: successes, challenges, and strategies--proceedings of the 5th annual BCR-ABL1 positive and BCR-ABL1 negative myeloproliferative neoplasms workshop.Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotiniConsiderations in the management of patients with Philadelphia chromosome-positive chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy.Evaluation of the Cepheid GeneXpert BCR-ABL assay.Dry-reagent disposable dipstick test for visual screening of seven leukemia-related chromosomal translocationsCurrent survival measures reliably reflect modern sequential treatment in CML: correlation with prognostic stratifications.Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) stDasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value.Detection of ABL1 kinase mutations in Philadelphia-positive patients exhibiting an inadequate molecular response using restriction fragment mass polymorphism and its clinical significance: a single-center experience in Korea.Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products.
P2860
Q30156840-8EF4F7C4-362F-4E99-8F79-E5A2B6FC0A61Q30357011-D0DC7ECB-9209-492C-BEBB-3EA0497F3D9CQ33398716-6584F639-46CF-4D84-BA8D-50846C1D90E8Q33561232-26DA101F-DDBF-4EDE-BA98-AFD2952414A5Q33750753-AACA622D-4BBB-4B88-8C83-3C9E85299634Q35584176-A07B8788-94A3-408D-AAC3-40FB2DE59C8EQ35674595-BFD25E78-5E4C-4163-A5D1-9CFFCFC22B4CQ35694453-4879551D-0D45-4642-AB72-5020DA3476EEQ36153509-023BCE32-EC64-4225-96BC-865C0A045586Q36169022-EA546ECA-66F7-4337-9C55-9D25C6B840CCQ36237327-37900AF2-2E45-439E-8BE3-4578B6A42C81Q36485357-5EEE552F-D058-45D8-A76B-C45A4413E3E2Q36735557-B5FE5FE4-7AA7-406C-B73D-A7C93F6680A8Q36816579-1D6EAF47-0497-461A-9A03-D51DF78437B1Q36819555-CF27C608-A07E-4D07-98C2-30340A696BCCQ36846361-BF515D0B-8DF2-49AD-9247-05C49603FFCAQ37112773-B7CD7749-81ED-46C9-9DA4-B32C4B1F9901Q37143280-07FBA0F4-F4CA-4848-9E65-0872425FD3ACQ37148391-69DAC313-AE2C-4844-97F4-4A58B4E06781Q37163550-8254C988-74DE-4FCE-BF43-ECDA858123D5Q37363928-75638A85-587E-40E7-9B22-8D16DEDBED82Q37372801-2C42616B-A453-4083-A9C2-18AC05D841DEQ37618894-971A4F21-9D9C-46DA-AE5F-90E8B7BF31B3Q37810110-8DB647F2-2811-48DC-8240-8F960423A0A1Q37973402-BA24807C-E820-4BB9-BB03-58943ABA142CQ37979587-69128D0F-C5EB-4286-A097-B9F81D6FBD24Q38142258-66EE66ED-90F2-4867-9241-5748CAC385F0Q38811738-A2C9F0E9-9A9C-41B7-AF5B-EB09366BDCDEQ39410543-390B2909-ACDA-4367-82F7-C7AF808AD425Q40131183-2CCC71C7-44DF-453F-9FD9-EA96B71B4895Q41594071-04B59D07-9D6A-4967-8AA0-BB16D88B999FQ41768439-A4F79A20-BBEF-4B1F-8F1A-2A6B7D41D6D2Q42117946-F399343E-0D6E-4560-A475-97573BBE96A2Q42793913-AE695DAA-72FC-4396-805F-3FADE690F204Q42854100-EB837A3C-7C1B-4B6F-AB9D-CB785E359922Q44394170-E9ACFB2F-DE20-40B7-BFDA-F3F3015C0EE6Q45024357-6B779395-8A65-4942-B74F-CD3BDBC930E5Q45916397-87CF710B-8BC2-46B1-976E-EEDDB105AA4DQ46594195-33E57271-5743-4AB1-8D3A-B91A220B914DQ46735722-52DC9FD5-FF81-491F-9F15-12554B8BA8A0
P2860
BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
BCR-ABL mRNA levels at and aft ...... ate-treated patients with CML.
@ast
BCR-ABL mRNA levels at and aft ...... ate-treated patients with CML.
@en
type
label
BCR-ABL mRNA levels at and aft ...... ate-treated patients with CML.
@ast
BCR-ABL mRNA levels at and aft ...... ate-treated patients with CML.
@en
prefLabel
BCR-ABL mRNA levels at and aft ...... ate-treated patients with CML.
@ast
BCR-ABL mRNA levels at and aft ...... ate-treated patients with CML.
@en
P2093
P2860
P1433
P1476
BCR-ABL mRNA levels at and aft ...... ate-treated patients with CML.
@en
P2093
Ashlie A Tronnes
Michael J Mauro
Michael W Deininger
Motomi Mori
Solange Mongoue-Tchokote
Thuan Tran
P2860
P304
P356
10.1182/BLOOD-2005-11-4406
P407
P577
2006-02-07T00:00:00Z